a physician a building location a clinical trial a department
menu
BCM - Baylor College of Medicine

Giving life to possible

Clinical Trials

Administration of HER2 Chimeric Receptor and TGFB Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects with Advanced HER2 Positive Lung Malignancy (H-24486) (H-24486)

Administration of HER2 Chimeric Receptor and TGFB Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects with Advanced HER2 Positive Lung Malignancy: This study evaluates T cells genetically modified to recognize a protein expressed on some lung cancer cells and to be resistant to TGFB. For more information:http://www.clinicaltrials.gov/ct2/show/NCT00889954